BioCentury | Dec 19, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Afexa for C$0.85 per share, or about C$87.7 million ($85.7 million) (see BioCentury, Nov. 7). Afexa Life Sciences Inc....
BioCentury | Nov 7, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...million shares, or 81.6% of Afexa's outstanding shares. Valeant said it would acquire the remaining Afexa...
...shares in a subsequent acquisition transaction. Last month, Valeant extended its tender offer to acquire Afexa...
...C$0.85 per share from its initial offer of C$0.71 per share (see BioCentury, Oct. 24). Afexa Life Sciences Inc....
BioCentury | Oct 24, 2011
Company News

Afexa management update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta Business: Nutraceuticals Hired: Thomas Schlader as president and CEO, while remaining president of Valeant Pharmaceuticals International Inc. 's Valeant Canada Ltd. subsidiary WIR Staff...
BioCentury | Oct 24, 2011
Company News

Afexa board of directors update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta Business: Nutraceuticals Appointed: Robert Chai-Onn as chairman, while remaining EVP, general counsel and corporate secretary of Valeant Pharmaceuticals International Inc. WIR Staff...
BioCentury | Oct 24, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Valeant extended its tender offer to acquire Afexa for C$0.85 per share, or about C$87.7 million...
...73.8% of outstanding shares, had been tendered. Last month, Valeant increased its offer to acquire Afexa...
...Quebec), which made an unsolicited offer to acquire Afexa for C$0.81 per share, said no Afexa...
BioCentury | Oct 10, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Paladin said last week that no Afexa shares would be taken up when its offer expired...
...EDT on Oct. 7 because a basic condition of its unsolicited tender offer to acquire Afexa...
...in the termination fee that Afexa would owe Valeant under the latter's tender offer for Afexa...
BioCentury | Oct 3, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Valeant increased its tender offer to acquire Afexa to C$0.85 per share in cash after Paladin...
...to C$0.85 per share in cash after Paladin increased its unsolicited tender offer to acquire Afexa...
...offer of C$0.71 per share. Valeant said it is able to attribute more value to Afexa...
BioCentury | Sep 19, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Valeant began its tender offer to acquire Afexa for C$0.71 per share in cash, or about...
...to 8 p.m. EDT on Sept. 28 from Sept. 15 its tender offer to acquire Afexa...
...was reviewing the terms of Valeant's offer and considering its options (see BioCentury, Sept. 5). Afexa Life Sciences Inc....
BioCentury | Sep 5, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Valeant will acquire Afexa for C$0.71 per share in cash, or about C$76 million ($77.6 million...
...in cash, or about C$76 million ($77.6 million). The price is a 20% premium to Afexa's...
...million ($3.8 million) termination fee. Afexa's board unanimously recommends Valeant's offer. Scotia Capital is advising Afexa...
BioCentury | Aug 29, 2011
Company News

Afexa nutraceuticals news

...The Toronto Stock Exchange said it will automatically defer acceptance of Afexa's new shareholder rights plan...
...be entitled to purchase shares of common stock at a significant discount to market prices. Afexa...
...shares. Afexa's board reaffirmed its recommendation that shareholders reject Paladin's offer (see BioCentury, Aug. 15). Afexa Life Sciences Inc....
Items per page:
1 - 10 of 20
BioCentury | Dec 19, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Afexa for C$0.85 per share, or about C$87.7 million ($85.7 million) (see BioCentury, Nov. 7). Afexa Life Sciences Inc....
BioCentury | Nov 7, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...million shares, or 81.6% of Afexa's outstanding shares. Valeant said it would acquire the remaining Afexa...
...shares in a subsequent acquisition transaction. Last month, Valeant extended its tender offer to acquire Afexa...
...C$0.85 per share from its initial offer of C$0.71 per share (see BioCentury, Oct. 24). Afexa Life Sciences Inc....
BioCentury | Oct 24, 2011
Company News

Afexa management update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta Business: Nutraceuticals Hired: Thomas Schlader as president and CEO, while remaining president of Valeant Pharmaceuticals International Inc. 's Valeant Canada Ltd. subsidiary WIR Staff...
BioCentury | Oct 24, 2011
Company News

Afexa board of directors update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta Business: Nutraceuticals Appointed: Robert Chai-Onn as chairman, while remaining EVP, general counsel and corporate secretary of Valeant Pharmaceuticals International Inc. WIR Staff...
BioCentury | Oct 24, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Valeant extended its tender offer to acquire Afexa for C$0.85 per share, or about C$87.7 million...
...73.8% of outstanding shares, had been tendered. Last month, Valeant increased its offer to acquire Afexa...
...Quebec), which made an unsolicited offer to acquire Afexa for C$0.81 per share, said no Afexa...
BioCentury | Oct 10, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Paladin said last week that no Afexa shares would be taken up when its offer expired...
...EDT on Oct. 7 because a basic condition of its unsolicited tender offer to acquire Afexa...
...in the termination fee that Afexa would owe Valeant under the latter's tender offer for Afexa...
BioCentury | Oct 3, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Valeant increased its tender offer to acquire Afexa to C$0.85 per share in cash after Paladin...
...to C$0.85 per share in cash after Paladin increased its unsolicited tender offer to acquire Afexa...
...offer of C$0.71 per share. Valeant said it is able to attribute more value to Afexa...
BioCentury | Sep 19, 2011
Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

...Valeant began its tender offer to acquire Afexa for C$0.71 per share in cash, or about...
...to 8 p.m. EDT on Sept. 28 from Sept. 15 its tender offer to acquire Afexa...
...was reviewing the terms of Valeant's offer and considering its options (see BioCentury, Sept. 5). Afexa Life Sciences Inc....
BioCentury | Sep 5, 2011
Company News

Afexa, Valeant Pharmaceuticals deal

...Valeant will acquire Afexa for C$0.71 per share in cash, or about C$76 million ($77.6 million...
...in cash, or about C$76 million ($77.6 million). The price is a 20% premium to Afexa's...
...million ($3.8 million) termination fee. Afexa's board unanimously recommends Valeant's offer. Scotia Capital is advising Afexa...
BioCentury | Aug 29, 2011
Company News

Afexa nutraceuticals news

...The Toronto Stock Exchange said it will automatically defer acceptance of Afexa's new shareholder rights plan...
...be entitled to purchase shares of common stock at a significant discount to market prices. Afexa...
...shares. Afexa's board reaffirmed its recommendation that shareholders reject Paladin's offer (see BioCentury, Aug. 15). Afexa Life Sciences Inc....
Items per page:
1 - 10 of 20